Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;7(10):ofaa407.
doi: 10.1093/ofid/ofaa407. eCollection 2020 Oct.

Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1

Beatriz Sierra  1 , Ana B Pérez  1 , Eglis Aguirre  1 , Claudia Bracho  1 , Odalys Valdés  2 , Narciso Jimenez  3 , Waldemar Baldoquin  4 , Guelsys Gonzalez  2 , Lilia M Ortega  5 , Maria C Montalvo  6 , Sonia Resik  7 , Delmis Alvarez  8 , Maria G Guzmán  9
Affiliations

Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1

Beatriz Sierra et al. Open Forum Infect Dis. .

Abstract

Early recognition of severe forms of coronavirus disease 2019 (COVID-19) is essential for an opportune and effective intervention, reducing life-risking complications. An altered inflammatory immune response seems to be associated with COVID-19's pathogenesis and progression to severity. Here we demonstrate the utility of early nasopharyngeal swab samples for detection of the early expression of immune markers and the potential value of CCL2/MCP-1 in predicting disease outcome.

Keywords: COVID-19; chemokines; cytokines; inflammation; prognostic biomarkers.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Relative gene expression of immune mediators in nasopharyngeal swab samples from coronavirus disease 2019 cases and controls. A, Expression of TNFα transcripts in different study groups of subjects: controls (samples from 16 healthy individuals confirmed as negative for severe acute respiratory syndrome coronavirus 2); favorable (23 subjects with favorable evolution: 12 asymptomatic subjects and 11 patients with mild disease); unfavorable (15 patients with unfavorable evolution: 9 very symptomatic patients and 6 who required intensive care; of these 6, 3 recovered and 3 died). B, Expression of CCL2/MCP-1 transcripts in those 3 groups. C, Expression of CCL3/MIP-1α transcripts in the 3 groups. D, Expression of TGFβ transcripts in the 3 groups. mRNA was determined for real-time reverse transcription polymerase chain reaction analysis, and the genes/housekeeping gene ratio was determined according to the delta/delta Ct method. Data are shown as dot plot graphics, on a log scale. Each dot plot shows statistic data about the gene expression determination. The central horizontal line in the dot marks the median of the samples; the hinges mark the ranges. Statistically significant differences in cytokine production among groups are indicated with horizontal lines over the dots. A P < .05 was considered statistically significant. P > .05 was considered not statistically significant. *P < .05; **P < .01; ***P < .001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506. - PMC - PubMed
    1. Chu CM, Poon LL, Cheng VC, et al. Initial viral load and the outcomes of SARS. CMAJ 2004; 171:1349–52. - PMC - PubMed
    1. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39:529–39. - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, et al. ; HLH Across Speciality Collaboration, UK COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–4. - PMC - PubMed
    1. World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance, 21 March 2020 2020. Available at: https://apps.who.int/iris/handle/10665/331509. Accessed 24 May 2020.